Track market-moving stories before they get noisy

DETROIT — Goodyear Tire & Rubber CEO Mark Stewart sits in the vehicle bay of a tire shop where the company is launching a new retail experience for customers.

There's a freshly painted black facade on the revamped Detroit store, with the words "Motor City" added in white flanking Goodyear's winged foot logo. It's dressed up for a private event tied to a nearby annual car festival called the Woodward Dream Cruise.

But despite the stylish touches, it's still a tire shop. The smell of rubber and oil remains in the air, and the sound of workers changing tires combines with music from a DJ inside the shop's waiting room.

The scene symbolizes Stewart's ongoing "Goodyear Forward" turnaround plan. He's trying to make tires — a historically dirty business — more attractive to investors and friendlier for consumers.

"We have made so much progress, and when you think about it from the standpoint of the Goodyear Forward program, it was really to get our feet back on the ground towards being the iconic company that we always were," Stewart, wearing an unbuttoned navy blue Goodyear technician shirt, told CNBC during an interview at the shop.

But while Goodyear is well known for burning rubber, it's also burning cash as it restructures, tries to refinance, and pays down years of debt.

The company's capital expenditures were roughly $2 billion combined in 2024 and 2025, with expectations of $725 million this year. Its debt remained above $7 billion at the end of the second quarter.

Goodyear's net loss was $453 million through the first half of the year, while its operating income was $131 million, or a 1.6% margin. 

Under the turnaround plan, Stewart wanted Goodyear to reach a 10% operating margin by the end of last year. Instead, that came in at 8.5% in the fourth quarter, and it's still an outstanding goal for the company to hit that mark.

"We're working on getting to that double-digit margin, and we're working on meaningfully generating cash flow," Stewart said. "It's been a long time since Goodyear's done that. That we absolutely must do."

The automotive veteran was named CEO of Goodyear after leaving Chrysler parent Stellantis in January 2024. Since then, shares of the company have fallen more than 50% despite Goodyear achieving many of the milestones he's set out to accomplish with the plan.

Stewart doesn't make excuses for missing the targets, even though Goodyear's business, like many, has been impacted by tariffs, inflated raw material costs, and the expansion of cheaper Chinese products.  

"We still have a lot of geopolitical headwinds that we're working through … a lot of headwinds with raw material indexes and a bit of the hangover from the tariff environment," he said, adding that overseas manufacturers continue to have cost advantages compared to Goodyear.

Goodyear Tire & Rubber Co. stock

Goodyear's raw material costs are expected to be roughly flat year over year, but a $200 million headwind in the second half, largely due to higher commodity costs associated with the conflict in the Middle East, according to the company and Wall Street analysts.

"Goodyear has faced many big challenges over the past few years, ranging from slower consumer (and commercial) demand, to rising raw material costs, to higher capital expenditures (capex), to low-priced Asian imports (into the U.S.), and, more recently, to trade and tariff legislation. It hasn't been easy for Goodyear," Argus analyst Bill Selesky said in an Aug. 17 investor note.

Goodyear is rated a hold with a price target of $7.60, according to average analyst ratings compiled by FactSet. Its shares closed Friday at $6.35, down 27% this year.

Goodyear Forward rolls onThe Goodyear Forward turnaround strategy was initially expected to be a two-year plan that went through last year, but the CEO has continued it as he and his executive team map out what's next for the 128-year-old Akron, Ohio-based company.

"At the right time, we will announce that," Stewart said. "We continue to press ahead to the next challenges and make sure we get the business in the right space."

The Goodyear Forward plan had already been released when Stewart was named incoming CEO, but he has made it his own, including by adding cuts and cost savings. The turnaround plan has cut roughly $1.5 billion in annualized costs, according to the company.

Part of Stewart's plan has been to move Goodyear more into the premium tire segment, including by selling off units such as its Dunlop brand. It also plans to launch more than 1,600 new products this year, most of which are in higher-end segments with bigger margins.

The product restructuring comes as non-U.S. brands, especially Asia's Sumitomo and Yokohama, have been expanding globally with cheaper products in lower-end segments, according to Stewart.

Similar to how Chinese automakers have grown outside their own country, tire manufacturers have also been turning to more exports, including the U.S.

"We are not going to compete against a $6 or $10 converted tire. That's not who we are as Goodyear," Stewart said, referring to the manufacturing cost required to convert raw materials into a finished tire.

Despite global challenges, Goodyear's Asia-Pacific region is a bright spot for the company. Its segment operating income for the second quarter was $63 million, with an operating margin of 12.7%.

watch now

Its U.S. operations have been a main drag on the company's financials. Stewart is trying to turn that around as consumer demand slows.

The company said its cash burn is expected to continue into 2027 but moderate as the announced closure next year of a plant in Fayetteville, North Carolina, is expected to improve its Americas segment operating income by $270 million annually.

"We had to take a very difficult decision, but a necessary one to announce the closure of our Fayetteville, North Carolina facility. We absolutely didn't take that lightly, but we just didn't have a pathway to be competitive out of that facility," Stewart said. 

The Goodyear Forward plan was prompted by activist investor Elliott Investment Management revealing a stake in the company in 2023. A spokesperson for Elliott, which supported three new Goodyear board members, declined to comment on the company or the firm's current ownership status.

Goodyear blimps flying highPart of the Goodyear Forward strategy is to increase focus on marketing and advertising to connect with customers to reinforce the brand.

A large part of that — both physically and financially — comes from the company's iconic Goodyear blimps, which have flown as giant advertisements for more than a century.

"The blimp team and the marketing team have really embraced it. So we do a lot of activation around the blimp to literally sell tires," Stewart said. "When the blimp media marketing has their hat on, it's always in context of 'How do we tie this to the tires?'"

Stewart said Goodyear has leaned into the promotion, using social media platforms to tout its aircraft — and their connection to tires — and launching "buy to fly" campaigns in which tire retailers and consumers can win flights aboard its blimps. 

The company was showing off its revamped store alongside a Detroit event that attracts hundreds of thousands of car enthusiasts along a 16-mile stretch annually. To celebrate and get its advertising in front of tire buyers, it held a rare double-blimp appearance, according to the company. It also featured a collection of smaller "mini blimps."

"We've always made the tires worth bragging about," Stewart said. "We're just reminding people now, and that ties into our marketing and advertising as well."

CORRECTION: An earlier version of this story incorrectly said two Japanese companies, Sumitomo and Yokohama, are based in China.

It has been about a month since the last earnings report for United Parcel Service (UPS - Free Report) . Shares have added about 1% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is UPS due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for United Parcel Service, Inc. before we dive into how investors and analysts have reacted as of late.

Earnings Beat at UPS in Q2Quarterly adjusted earnings of $1.76 per share increased 13.5% year over year. The figure beat the Zacks Consensus Estimate of $1.65 by 6.7%. Revenues rose 7.6% to $22.83 billion and surpassed the consensus estimate of $21.75 billion by 5%. Growth across all three segments supported the top line, while International revenue per piece climbed 18.9%.

UPS' Domestic Revenues Rise on Strong PricingU.S. Domestic Package revenues increased 6% year over year to $14.93 billion, driven by a 9.3% improvement in revenue per piece. Average daily package volume declined to 16 million from 16.6 million a year earlier, indicating that pricing more than offset lower shipment activity.

Adjusted operating profit advanced 21% year over year to $1.19 billion. The adjusted operating margin expanded 100 basis points to 8%, even as adjusted cost per piece increased 8% to $13.09. The margin improvement reflects progress from UPS’ network reconfiguration and efficiency initiatives.

United Parcel Service’s International Sales JumpInternational Package revenues increased 12.5% year over year to $5.04 billion. The segment delivered the strongest revenue growth among UPS’ operating businesses, aided by the sharp increase in revenue per piece.

Adjusted operating profit declined 8.7% year over year to $623 million. The adjusted operating margin contracted to 12.4% from 15.2% in the prior-year quarter, showing that higher revenue did not translate into operating profit growth as segment expenses increased.

UPS Supply Chain Business Delivers Profit GrowthSupply Chain Solutions revenues rose 7.8% year over year to $2.86 billion. The improvement was primarily driven by growth in forwarding and logistics operations, including the healthcare business.

Adjusted operating profit increased 37.3% year over year to $291 million. The adjusted operating margin expanded 220 basis points to 10.2%, reflecting stronger operating leverage and making Supply Chain Solutions the company’s most improved segment on a profitability basis.

United Parcel Service Expands Adjusted MarginConsolidated adjusted operating profit rose 12% year over year to $2.10 billion. The adjusted operating margin increased to 9.2% from 8.8%, supported by profit growth in the U.S. Domestic Package and Supply Chain Solutions businesses.

On a GAAP basis, operating profit fell to $930 million from $1.82 billion, while diluted earnings declined to 71 cents per share from $1.51. Results included $1.17 billion of pretax transformation strategy costs, primarily related to employee separation expenses associated with the Driver Choice Program.

UPS Network Changes Produce Cost BenefitsUPS generated approximately $1.2 billion of benefits from its network reconfiguration and Efficiency Reimagined initiatives during the first six months of 2026. Management expects these programs to deliver approximately $3 billion of benefits for the full year.

The company completed its planned Amazon volume reduction and related network changes during the period. UPS has reduced its operational workforce and closed daily operations at certain facilities as it aligns network capacity with its changing shipment mix. The broader initiatives are expected to conclude by 2027.

United Parcel Service’s Free Cash Flow More Than DoublesCash provided by operating activities increased to $3.08 billion in the first six months of 2026 from $2.67 billion a year earlier. Capital expenditures declined to $1.72 billion from $2 billion.

Free cash flow more than doubled to $1.57 billion from $742 million. The improvement gives UPS greater flexibility to fund network investments, meet financial obligations and return capital to shareholders.

UPS’ 2026 Outlook RaisedManagement raised its full-year consolidated revenue outlook to approximately $91.2 billion from the prior view of $89.7 billion. UPS also lifted its adjusted operating profit target to approximately $8.65 billion and adjusted earnings guidance to approximately $7.22 per share.

Capital expenditures are still projected at roughly $3 billion. Dividend payments are expected to total around $5.4 billion, subject to board approval, while the effective tax rate is projected to be approximately 23%.

How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended downward during the past month.

The consensus estimate has shifted -6.4% due to these changes.

VGM ScoresCurrently, UPS has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, UPS has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Algert Global LLC reduced its stake in shares of Globe Life Inc. (NYSE:GL – Free Report) by 49.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,637 shares of the company’s stock after selling 34,510 shares during the quarter. Algert Global LLC’s holdings in Globe Life were worth $6,368,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Globe Life by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 10,090,885 shares of the company’s stock worth $1,411,311,000 after acquiring an additional 86,349 shares in the last quarter. BlackRock Inc. bought a new position in shares of Globe Life during the second quarter valued at $987,901,000. Invesco Ltd. grew its stake in shares of Globe Life by 2.7% in the fourth quarter. Invesco Ltd. now owns 3,948,676 shares of the company’s stock worth $552,262,000 after acquiring an additional 102,445 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Globe Life by 10.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,353,192 shares of the company’s stock valued at $327,479,000 after buying an additional 217,331 shares during the period. Finally, Morgan Stanley increased its position in Globe Life by 7.2% during the fourth quarter. Morgan Stanley now owns 1,860,257 shares of the company’s stock valued at $260,176,000 after acquiring an additional 125,567 shares during the last quarter. Institutional investors own 81.61% of the company’s stock.

Analyst Ratings Changes Several analysts have issued reports on GL shares. Keefe, Bruyette & Woods cut their price target on Globe Life from $192.00 to $190.00 and set an “outperform” rating for the company in a report on Friday, July 24th. Jefferies Financial Group raised their price objective on Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a research report on Friday, July 10th. Wells Fargo & Company increased their price objective on shares of Globe Life from $172.00 to $193.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. JPMorgan Chase & Co. lifted their target price on Globe Life from $181.00 to $201.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Finally, TD Cowen raised their price objective on shares of Globe Life from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $191.67.

Read Our Latest Report on Globe Life Insider Activity at Globe Life In other news, Director Cheryl Alston sold 8,258 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $179.24, for a total transaction of $1,480,163.92. Following the sale, the director owned 16,621 shares of the company’s stock, valued at approximately $2,979,148.04. This trade represents a 33.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Thomas Peter Kalmbach sold 25,650 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $178.58, for a total transaction of $4,580,577.00. Following the completion of the transaction, the chief financial officer directly owned 50,568 shares in the company, valued at $9,030,433.44. This trade represents a 33.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 151,908 shares of company stock worth $27,239,981 over the last ninety days. Company insiders own 2.11% of the company’s stock.

Globe Life Stock Performance Shares of GL opened at $175.56 on Thursday. The stock has a 50-day moving average of $178.63 and a two-hundred day moving average of $159.23. The stock has a market cap of $13.49 billion, a P/E ratio of 11.66 and a beta of 0.48. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.07 and a current ratio of 0.07. Globe Life Inc. has a one year low of $127.85 and a one year high of $191.55.

Globe Life (NYSE:GL – Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $3.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.67 by ($0.06). The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.59 billion. Globe Life had a net margin of 19.58% and a return on equity of 20.52%. The company’s revenue was up 8.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.05 earnings per share. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. As a group, research analysts predict that Globe Life Inc. will post 15.71 EPS for the current year.

Globe Life Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Monday, October 5th will be given a dividend of $0.33 per share. The ex-dividend date of this dividend is Monday, October 5th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 0.8%. Globe Life’s dividend payout ratio (DPR) is presently 8.76%.

Globe Life declared that its Board of Directors has initiated a share repurchase program on Monday, August 10th that allows the company to buyback $2.50 billion in outstanding shares. This buyback authorization allows the company to purchase up to 17.7% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

About Globe Life (Free Report)

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.

Read More Five stocks we like better than Globe Life Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks? Want to see what other hedge funds are holding GL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globe Life Inc. (NYSE:GL – Free Report).

Receive News & Ratings for Globe Life Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globe Life and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of New York Mellon Corp lessened its stake in Costco Wholesale Corporation (NASDAQ:COST – Free Report) by 5.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,215,058 shares of the retailer’s stock after selling 176,566 shares during the period. Bank of New York Mellon Corp owned approximately 0.72% of Costco Wholesale worth $3,007,590,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in shares of Costco Wholesale during the 4th quarter valued at about $27,000. Lifetime Wealth Management P.C. purchased a new stake in shares of Costco Wholesale during the 4th quarter valued at about $28,000. Mcguire Capital Advisors Inc. bought a new position in shares of Costco Wholesale in the 4th quarter worth approximately $28,000. Entrust Financial LLC purchased a new position in shares of Costco Wholesale in the fourth quarter worth approximately $31,000. Finally, Joseph Group Capital Management purchased a new position in shares of Costco Wholesale in the fourth quarter worth approximately $33,000. 68.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Costco Wholesale In related news, Director Kenneth D. Denman sold 885 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $957.45, for a total value of $847,343.25. Following the transaction, the director directly owned 4,779 shares of the company’s stock, valued at approximately $4,575,653.55. The trade was a 15.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.10% of the company’s stock.

Key Costco Wholesale News Here are the key news stories impacting Costco Wholesale this week: Positive Sentiment: Costco’s membership program is being highlighted as an underappreciated growth engine. Recurring membership fees support profitability and customer loyalty, potentially providing a durable catalyst if renewal rates and membership growth remain strong. Costco Has a Secret Growth Engine Positive Sentiment: Costco’s partnership with SCAN Health Plan to offer a limited selection of Medicare Advantage and Medicare Supplemental plans gives the retailer a potential new membership and services opportunity. The near-term financial impact is unclear, but the initiative could broaden Costco’s ecosystem and customer reach. Healthcare CEO partnering with Costco outlines Medicare offerings Neutral Sentiment: Golden Reserve Retirement increased its Costco position by 133.9%, purchasing 592 additional shares. The investment signals confidence, but the resulting holding of only 1,034 shares is too small to materially affect Costco’s outlook. Golden Reserve increases Costco position Neutral Sentiment: Consumer-focused articles highlighting savings, popular products and school snacks reinforce Costco’s value proposition, but they do not provide new financial information likely to move the stock. Coverage also reported zero short interest, though the figures appear incomplete or unreliable. Negative Sentiment: Costco is refunding customers for duties it says were unlawfully collected on certain tariffed goods while fighting a related class-action lawsuit. Refund costs, possible legal liabilities and reputational damage could pressure results, although the refunds may help preserve customer trust. Why Is Costco Refunding Tariff Duties? Costco Wholesale Trading Down 0.4% Shares of COST stock opened at $956.12 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.61 and a current ratio of 1.07. The stock has a fifty day simple moving average of $946.25 and a two-hundred day simple moving average of $980.63. The firm has a market capitalization of $424.02 billion, a PE ratio of 48.09, a PEG ratio of 4.57 and a beta of 0.87. Costco Wholesale Corporation has a 52-week low of $844.06 and a 52-week high of $1,096.50.

Costco Wholesale (NASDAQ:COST – Get Free Report) last announced its quarterly earnings data on Thursday, May 28th. The retailer reported $4.93 EPS for the quarter, missing the consensus estimate of $4.94 by ($0.01). The business had revenue of $70.53 billion during the quarter, compared to analysts’ expectations of $70.12 billion. Costco Wholesale had a net margin of 3.01% and a return on equity of 28.04%. During the same quarter in the previous year, the firm earned $4.28 earnings per share. On average, analysts predict that Costco Wholesale Corporation will post 20.42 EPS for the current fiscal year.

Costco Wholesale Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Friday, August 7th. Investors of record on Friday, July 24th were paid a dividend of $1.47 per share. This represents a $5.88 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, July 24th. Costco Wholesale’s dividend payout ratio (DPR) is 29.58%.

Analyst Ratings Changes COST has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,120.00 target price on shares of Costco Wholesale in a report on Thursday, August 6th. JPMorgan Chase & Co. cut their price objective on shares of Costco Wholesale from $1,110.00 to $1,100.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Oppenheimer boosted their price objective on shares of Costco Wholesale from $1,100.00 to $1,160.00 and gave the company an “outperform” rating in a research report on Tuesday, May 19th. Citigroup started coverage on Costco Wholesale in a research note on Thursday, June 18th. They issued a “neutral” rating and a $1,020.00 price objective for the company. Finally, Mizuho set a $1,100.00 target price on Costco Wholesale in a report on Monday, June 1st. Twenty-two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Costco Wholesale currently has a consensus rating of “Moderate Buy” and an average price target of $1,059.53.

View Our Latest Stock Report on Costco Wholesale

Costco Wholesale Profile (Free Report)

Costco Wholesale Corporation operates a global chain of membership-only warehouse clubs that sell a wide array of merchandise in bulk at discounted prices. The company’s product mix includes groceries, fresh and frozen food, household goods, electronics, apparel, and seasonal items, augmented by its prominent private-label brand, Kirkland Signature. Costco’s business model centers on annual membership fees and high-volume, low-margin sales, designed to drive repeat purchasing and strong customer loyalty among both consumers and small-business buyers.

Beyond merchandise, Costco provides a range of ancillary services that complement its warehouses, including gasoline stations, pharmacy and optical services, hearing aid centers, photo services, and travel and insurance products.

Further Reading Five stocks we like better than Costco Wholesale Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks? Want to see what other hedge funds are holding COST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Costco Wholesale Corporation (NASDAQ:COST – Free Report).

Receive News & Ratings for Costco Wholesale Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Costco Wholesale and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of Nova Scotia bought a new position in First Solar, Inc. (NASDAQ:FSLR – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,865 shares of the solar cell manufacturer’s stock, valued at approximately $3,271,000.

Several other large investors also recently made changes to their positions in the company. Commonwealth Retirement Investments LLC acquired a new position in shares of First Solar during the fourth quarter worth approximately $26,000. Reflection Asset Management bought a new position in First Solar in the 4th quarter worth approximately $26,000. Strategic Wealth Investment Group LLC acquired a new stake in First Solar in the 2nd quarter valued at approximately $26,000. Larson Financial Group LLC increased its position in First Solar by 117.0% in the 4th quarter. Larson Financial Group LLC now owns 102 shares of the solar cell manufacturer’s stock valued at $27,000 after acquiring an additional 55 shares during the period. Finally, Elyxium Wealth LLC bought a new stake in First Solar during the 4th quarter valued at $30,000. Institutional investors and hedge funds own 92.08% of the company’s stock.

First Solar Price Performance FSLR opened at $206.82 on Wednesday. The company has a market capitalization of $22.22 billion, a PE ratio of 12.75, a price-to-earnings-growth ratio of 0.45 and a beta of 1.75. First Solar, Inc. has a fifty-two week low of $182.99 and a fifty-two week high of $320.95. The business has a 50-day moving average of $226.41 and a 200-day moving average of $223.78.

First Solar (NASDAQ:FSLR – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The solar cell manufacturer reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.90 by $1.02. First Solar had a net margin of 32.47% and a return on equity of 18.02%. The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the company posted $3.18 earnings per share. First Solar’s revenue for the quarter was down 3.4% on a year-over-year basis. On average, equities research analysts expect that First Solar, Inc. will post 17.77 earnings per share for the current fiscal year. Analysts Set New Price Targets A number of research analysts have issued reports on FSLR shares. UBS Group boosted their price target on First Solar from $290.00 to $330.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. The Goldman Sachs Group lifted their price objective on shares of First Solar from $300.00 to $310.00 in a research note on Friday, May 1st. Freedom Capital raised shares of First Solar from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. HSBC raised shares of First Solar from a “hold” rating to a “buy” rating in a research note on Friday, August 7th. Finally, Evercore restated a “positive” rating and set a $218.00 price target on shares of First Solar in a research report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $264.44.

View Our Latest Research Report on FSLR

Insider Buying and Selling at First Solar In other news, insider Caroline Stockdale sold 10,628 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $275.60, for a total transaction of $2,929,076.80. Following the transaction, the insider owned 23,792 shares in the company, valued at approximately $6,557,075.20. The trade was a 30.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jason E. Dymbort sold 3,700 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $249.38, for a total value of $922,706.00. Following the transaction, the general counsel owned 5,624 shares in the company, valued at $1,402,513.12. This represents a 39.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,709 shares of company stock valued at $6,386,163 in the last three months. 0.39% of the stock is owned by insiders.

Key First Solar News Here are the key news stories impacting First Solar this week:

Positive Sentiment: Value appeal: Zacks identifies First Solar as a top-ranked value stock, potentially supporting investor interest given its reported earnings strength and relatively low valuation metrics. First Solar Is a Top-Ranked Value Stock Neutral Sentiment: Short-interest data offers no actionable signal: The latest report lists short interest at zero shares and a zero-day days-to-cover ratio, unchanged from the prior period. Because the figures include an apparent calculation error (“NaN” increase), they should not be interpreted as evidence of either short covering or heightened bearish positioning. Negative Sentiment: Legal overhang intensifies: Multiple law firms are promoting a securities class action against First Solar and seeking investors to serve as lead plaintiff. The reported claims focus on alleged misrepresentations regarding underutilization of Series 6 module production and the costly challenges of expanding manufacturing operations in South Carolina. The allegations have not been proven, but the repeated announcements may weigh on sentiment by raising potential financial, legal and reputational risks. First Solar Investor Alert Levi and Korsinsky First Solar Lawsuit Alert About First Solar (Free Report)

First Solar, Inc (NASDAQ: FSLR) is a United States–based solar technology company best known for designing and manufacturing thin‑film photovoltaic (PV) modules that use cadmium telluride (CdTe) semiconductor technology. The company supplies PV modules and delivers integrated solar power solutions for utility‑scale projects, positioning itself as a provider of both components and complete solar energy systems rather than solely a parts supplier. First Solar was founded in 1999 and is headquartered in Tempe, Arizona.

Beyond module manufacturing, First Solar offers a range of project services including development support, engineering, procurement and construction (EPC) services, and operations and maintenance (O&M) for large-scale solar installations.

See Also Five stocks we like better than First Solar Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding FSLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for First Solar, Inc. (NASDAQ:FSLR – Free Report).

Receive News & Ratings for First Solar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Solar and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Gilead won EU approval for Trodelvy plus Keytruda in first-line metastatic TNBC with PD-L1 expression.Trodelvy cut disease progression or death risk by 35% versus chemotherapy plus Keytruda in ASCENT-04.Trodelvy sales rose 26% to $457 million in Q2, driven by stronger demand across breast cancers. Gilead Sciences, Inc.  (GILD - Free Report) recently announced that the European Commission (EC) has approved label expansion of the breast cancer drug Trodelvy (sacituzumab govitecan-hziy).

The EC granted marketing authorization to Trodelvy in combination with Merck’s (MRK - Free Report) Keytruda (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive score (CPS ≥10).

Trodelvy, a first-in-class Trop-2-directed antibody-drug conjugate (ADC), is already approved in several countries for second-line or later metastatic TNBC and in more than 50 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer (mBC).

Per GILD, Trodelvy plus Keytruda is the first and only ADC plus immunotherapy combination to be approved in first-line metastatic TNBC in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.

Shares of GILD have gained 20.4% year to date compared with the industry’s growth of 10.7%.

Image Source: Zacks Investment Research

More on EC’s Latest Label Expansion of GILD’s TrodelvyThe latest EC approval is based on positive results from the late-stage ASCENT-04/KEYNOTE-D19 study, which showed a statistically significant and clinically meaningful improvement in progression-free survival with Trodelvy plus Keytruda compared with standard-of-care chemotherapy plus Keytruda as a first-line treatment. In the study, Trodelvy reduced the risk of disease progression or death by 35% in patients with PD-L1-positive metastatic TNBC.

The latest decision follows the EC’s recent approval of Trodelvy as a monotherapy for adults with unresectable, locally advanced or metastatic TNBC who have not received prior systemic therapy for metastatic disease and are not eligible for PD-1 or PD-L1 inhibitor treatment.

Together, the approvals position Trodelvy as a potential backbone therapy for first-line metastatic TNBC in Europe, regardless of PD-L1 status. The expanded indication offers a new treatment option for patients with this aggressive form of breast cancer at the onset of metastatic disease.

Trodelvy is also approved in first-line mTNBC in the United States, either as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy or in combination with Keytruda (pembrolizumab) or Keytruda Qlex (subcutaneous injection of Keytruda) for patients whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.

The drug is currently being evaluated in multiple ongoing late-stage studies across a range of tumor types with high Trop-2 expression, including lung and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.

Merck and Gilead Sciences had earlier announced discontinuation of the phase III KEYNOTE-D46/EVOKE-03 study evaluating Trodelvy in combination with Keytruda as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 (TPS ≥50%).

GILD’s Efforts to Diversify Revenue BaseThe recent label expansions are expected to strengthen Trodelvy's commercial opportunity and reinforce its position as a key growth driver within Gilead's oncology portfolio.

Trodelvy sales increased 26% year over year to $457 million in the second quarter, driven by stronger demand across triple-negative and previously treated HR-positive/HER2-negative metastatic breast cancer.

GILD is looking to strengthen its oncology franchise and diversify its revenue base, which is highly concentrated on HIV business.

Gilead’s recent aggressive dealmaking strategy, including the acquisitions of Arcellx and Tubulis, underscores its commitment to diversifying beyond its core HIV franchise and expanding into higher-growth oncology and immunology markets.

Gilead recently delivered a strong second quarter, with both earnings and revenues exceeding expectations. The HIV franchise remains the principal growth engine, supported by Biktarvy's durability and rapid expansion of the prevention business.
Descovy and Yeztugo’s strong performance is boosting the top-line growth. Per GILD, Yeztugo has quickly become the leading long-acting PrEP option for new patient starts.

Approval of additional better treatments should bolster GILD’s HIV franchise in the wake of increasing competition from the likes of GSK plc (GSK - Free Report) .

HIV sales account for a major chunk of GSK’s Specialty Medicines portfolio. GSK continues to grow its HIV business, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato. The solid growth from these drugs has helped GSK combat the decline in Triumeq sales.

GILD’s Zacks Rank

The U.S. Food and Drug Administration ‌has approved Gilead Sciences' (GILD.O) once-daily oral combination pill for treatment of adults whose HIV infection has already been reduced to very low levels, the company said on Thursday.

The drug, branded Bixlenvo, combines Gilead's ​HIV medicines bictegravir and lenacapavir.

The wholesale acquisition cost for a 30-day supply of ​Bixlenvo is $4,595, a Gilead spokesperson told Reuters.

Bictegravir, the key component of ⁠the blockbuster treatment Biktarvy, is a widely recommended HIV drug with a high barrier ​to resistance.

Lenacapavir, marketed as Sunlenca for HIV treatment and as Yeztugo for HIV prevention, ​is a capsid inhibitor that targets the virus's protective shell to disrupt its multiplication.

Patients must take an initial two-day dose of Sunlenca, before taking Bixlenvo once daily. Gilead expects Bixlenvo to become available ​within days of approval.

The human immunodeficiency virus (HIV) attacks the body's immune system. Without treatment, ​it can lead to AIDS. There is currently no effective cure.

"The main advantage of this combination is ‌that ⁠it potentially offers a simpler option, in terms of pill burden, to patients who might currently be on more complex regimens due to a history of drug resistant virus," said Monika Shah, an infectious disease specialist at Memorial Sloan Kettering Cancer Center.

The approval ​was based on two ​late-stage studies in ⁠which Bixlenvo was as effective as complex multi-pill regimens or Biktarvy in keeping the virus suppressed after 48 weeks.

Bixlenvo is part of ​Gilead's multi-year strategy to expand its HIV portfolio, grounded in ​lenacapavir, Jared ⁠Baeten, the company's head of clinical development for virology, told Reuters. About 5% of people living with HIV in the United States take complex regimens involving more than one tablet ⁠a day, ​Baeten said.

The combination enters a competitive HIV-treatment market ​that includes Merck's (MRK.N) Idvynso, a once-daily two-drug pill approved in April for certain adults whose HIV-1 is already suppressed.

BNP Paribas boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 20.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,671 shares of the biopharmaceutical company’s stock after buying an additional 20,329 shares during the period. BNP Paribas’ holdings in Gilead Sciences were worth $14,992,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. State Street Corp raised its holdings in shares of Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after acquiring an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after buying an additional 1,195,269 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after buying an additional 3,046,688 shares during the last quarter. Finally, Norges Bank purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets In related news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the sale, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at $77,160,851.23. The trade was a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 105,000 shares of company stock valued at $14,238,120. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth A number of analysts recently commented on the company. Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Finally, HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $158.04. Get Our Latest Stock Report on GILD

Key Stories Impacting Gilead Sciences Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing Gilead Sciences Trading Down 2.1% Shares of GILD stock opened at $145.68 on Friday. The company has a 50 day moving average price of $134.25 and a 200 day moving average price of $136.62. The stock has a market capitalization of $180.64 billion, a P/E ratio of -54.56 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the company earned $2.01 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post -0.5 EPS for the current fiscal year.

Gilead Sciences Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s payout ratio is currently -122.85%.

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Featured Articles Five stocks we like better than Gilead Sciences 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop?

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

BlackRock Inc. acquired a new position in Enbridge Inc (NYSE:ENB – Free Report) (TSE:ENB) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,387,262 shares of the pipeline company’s stock, valued at approximately $183,623,000. BlackRock Inc. owned approximately 0.16% of Enbridge at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ENB. Deutsche Bank AG purchased a new stake in Enbridge in the 2nd quarter worth $1,850,502,000. Perigon Wealth Management LLC bought a new stake in Enbridge during the second quarter valued at about $570,000. Phillips Wealth Planners LLC purchased a new position in shares of Enbridge in the second quarter valued at about $304,000. Trust Co. of Vermont purchased a new position in shares of Enbridge in the second quarter valued at about $10,103,000. Finally, Principle Wealth Partners LLC bought a new position in shares of Enbridge in the second quarter worth about $796,000. 54.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes Several analysts recently issued reports on ENB shares. Royal Bank Of Canada increased their target price on Enbridge from $79.00 to $84.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. BMO Capital Markets restated a “market perform” rating on shares of Enbridge in a research note on Monday, August 3rd. Wolfe Research set a $50.00 price objective on shares of Enbridge in a report on Tuesday, August 4th. Canadian Imperial Bank of Commerce raised shares of Enbridge from a “neutral” rating to an “outperform” rating in a report on Thursday. Finally, Raymond James Financial downgraded shares of Enbridge from an “outperform” rating to a “market perform” rating in a report on Friday, July 31st. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Check Out Our Latest Research Report on Enbridge Key Headlines Impacting Enbridge Here are the key news stories impacting Enbridge this week:

Positive Sentiment: Enbridge agreed to form a joint venture with KKR and Apollo to fund approximately C$2.7 billion (US$1.95 billion) of expansions to its Westcoast natural gas pipeline system in British Columbia. The Aspen Point and Sunrise projects are already sanctioned and supported by long-term contracts, while third-party capital reduces Enbridge’s upfront funding requirements and capital burden. Enbridge and KKR form Westcoast pipeline joint venture Positive Sentiment: Enbridge is acquiring Salt Creek Midstream’s crude gathering business in the Delaware Basin for US$600 million. The assets include about 500 miles of infrastructure, full ownership of the Orla and Wink North systems, and a 50% stake in Delaware Crossing. The deal expands Enbridge’s Permian footprint, strengthens its integrated crude export network, and is expected to add contracted earnings and cash flow after closing. Enbridge to buy Salt Creek Midstream crude assets Neutral Sentiment: Air monitoring following a gas leak during work on Enbridge’s Line 5 in Michigan’s Upper Peninsula found no hazardous gas levels. The incident appears contained, but investors may continue to monitor potential safety, regulatory, and operational consequences. Air monitoring after Enbridge Line 5 leak Negative Sentiment: The Salt Creek acquisition requires US$600 million in cash, adding near-term capital outlay to a company that already carries substantial debt. The expected benefits also depend on transaction closing, project execution, and continued activity in the Permian Basin. Enbridge Price Performance Shares of Enbridge stock opened at $49.97 on Friday. The stock has a 50 day moving average of $53.73 and a 200 day moving average of $54.03. Enbridge Inc has a 12 month low of $45.03 and a 12 month high of $58.45. The firm has a market cap of $109.13 billion, a PE ratio of 26.72 and a beta of 0.58. The company has a current ratio of 0.72, a quick ratio of 0.66 and a debt-to-equity ratio of 1.69.

Enbridge (NYSE:ENB – Get Free Report) (TSE:ENB) last released its quarterly earnings data on Friday, July 31st. The pipeline company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.03. The business had revenue of $9.70 billion for the quarter, compared to the consensus estimate of $8.67 billion. Enbridge had a return on equity of 11.17% and a net margin of 7.20%.During the same quarter in the previous year, the company posted $0.65 EPS. On average, research analysts expect that Enbridge Inc will post 2.11 EPS for the current fiscal year.

Enbridge Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, August 14th will be paid a dividend of $0.97 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $3.88 dividend on an annualized basis and a yield of 7.8%. Enbridge’s dividend payout ratio is presently 147.06%.

Enbridge Profile (Free Report)

Enbridge Inc is a Calgary, Alberta–based energy infrastructure company that develops, owns and operates a diversified portfolio of energy transportation, distribution and generation assets. Its core activities include the operation of crude oil and liquids pipelines, natural gas transmission and distribution systems, and energy storage facilities. In addition to midstream transportation and storage, Enbridge has expanded into renewable power generation and energy transition projects, including wind, solar and utility-scale generation assets.

The company serves customers primarily in Canada and the United States and has interests in other international energy projects.

Read More Five stocks we like better than Enbridge Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Receive News & Ratings for Enbridge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enbridge and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways CF Industries and partners have begun construction of the $3.7B Blue Point One low-carbon ammonia plant.Blue Point One is set for 1.4M metric tons of annual capacity and is expected to start production in 2029.The plant is designed to capture and permanently sequester about 98% of carbon dioxide from production. CF Industries Holdings, Inc. (CF - Free Report) , JERA Co. and Mitsui & Co. have begun the construction of Blue Point One, a $3.7 billion low-carbon ammonia plant in Louisiana. The project is expected to strengthen CF’s position in the evolving low-carbon ammonia market by serving both traditional agricultural customers and emerging energy applications.

Blue Point One will have an annual production capacity of 1.4 million metric tons, making it the world’s largest low-carbon ammonia plant upon completion. The facility is expected to begin production in 2029. The project brings together the world’s largest producer of ammonia and Japan's largest energy company, JERA Co., with a pioneering investment and trading company, Mitsui & Co.

The project will use autothermal reforming technology and is designed to capture and permanently sequester approximately 98% of the carbon dioxide generated during production. This is expected to give the facility one of the lowest environmental footprints among large-scale ammonia plants.

CF Industries owns a 40% stake in the joint venture, with JERA holding 35% and Mitsui owning 25%. CF Industries will also invest an additional $550 million in shared infrastructure to support future ammonia production and fertilizer upgrades.

The development is further supported by Linde’s investment of more than $400 million in an on-site air-separation unit, while a joint venture between 1PointFive and Enbridge will transport and permanently sequester the captured carbon dioxide.

CF shares have gained 43.9% over the past year against the industry’s 43.5% decline.

Image Source: Zacks Investment Research

CF’s Zacks Rank & Key PicksCF currently carries a Zacks Rank #3 (Hold). 

Some better-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. (NOPMF - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avient Corporation (AVNT - Free Report) .

While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pinned at $1.4 per share, indicating a 185.71% year-over-year increase. NOPMF’sshares have gained 91.6% over the past year.

The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%.

The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’s shares have gained 20.3% over the past year.

Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI® (risankizumab) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD).

The application to the EMA is supported by the recently shared positive data from the Phase 3 AFFIRM study1 (NCT06063967), which evaluated the efficacy and safety of risankizumab SC as an induction treatment in adult patients with moderately to severely active CD, in those with and without prior advanced therapy failure.

"As treatment goals in Crohn's disease continue to evolve, it is important to provide therapies that can deliver meaningful outcomes from the earliest stages of treatment through long-term disease management," said Roopal Thakkar, M.D., executive vice president, research and development, and chief scientific officer, AbbVie. "This submission builds on the growing body of evidence supporting SKYRIZI and reflects our efforts to advancing treatment approaches that may help patients achieve important clinical and endoscopic outcomes."

In 2022, SKYRIZI became the first specific IL-23 inhibitor approved for the treatment of Crohn's disease in the European Union (EU) to treat adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.2 If approved, patients with moderately to severely active CD would have the option to receive their SKYRIZI induction doses via SC injection or through IV infusion and then continue subcutaneous maintenance doses every eight weeks. 

About Crohn's Disease
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.3,4 It is a progressive disease, meaning it gets worse over time and may lead to life-threatening complications or surgery.5,6 Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically but also emotionally and economically.7

About the AFFIRM Study1 
AFFIRM is a global, Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of SC dosing of risankizumab as an induction treatment in adult patients with moderately to severely active Crohn's disease. Co-primary endpoints were achievement of CDAI Clinical Remission (CDAI < 150) and achievement of endoscopic response at week 12. A total of 289 patients were randomized in a 2:1 ratio to risankizumab SC or placebo. Key demographics and baseline characteristics were generally balanced between the risankizumab SC and placebo groups; 65% of patients had previously failed advanced therapies for the treatment of CD. The study consists of three treatment periods: a placebo-controlled Period A (baseline to week 12) to evaluate the efficacy and safety of risankizumab SC induction treatment, an extended Period B (week 12 to 24) where patients received blinded or open-label treatments based on their clinical response at week 12, and a 52-week open-label extension Period C, where all patients receive the approved risankizumab maintenance treatment.1 More information on this trial can be found at www.clinicaltrials.gov (NCT06063967).8

About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.2 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.2,9

EU Indications and Important Safety Information about SKYRIZI® (risankizumab) 
Indications2 

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information 
Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution.

Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

AbbVie. Data on file ABVRRTI82775 SKYRIZI [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG; [June 2026] available at: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf. Accessed July 31, 2026. Crohn's & Colitis Foundation. The facts about inflammatory bowel diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed July 31, 2026. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf Mayo Clinic. Crohn's disease - Symptoms and causes. Mayo Clinic. Updated Dec 4, 2025. Accessed July 31, 2026. https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304 Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60. Kaplan G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150. Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT06063967. Accessed July 31, 2026. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc. SOURCE AbbVie

Empirical Asset Management LLC acquired a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,575 shares of the company’s stock, valued at approximately $1,403,000.

Several other large investors have also modified their holdings of ABBV. Brighton Jones LLC lifted its position in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. grew its position in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares during the last quarter. Ieq Capital LLC increased its stake in shares of AbbVie by 4.6% in the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after purchasing an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC increased its stake in shares of AbbVie by 117.3% in the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after purchasing an additional 612,702 shares during the period. 70.23% of the stock is owned by institutional investors.

Insider Buying and Selling In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Stock Down 0.8% ABBV stock opened at $256.08 on Friday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The company has a market cap of $452.44 billion, a PE ratio of 72.34, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30. The business’s 50-day simple moving average is $252.66 and its 200 day simple moving average is $228.87. AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the prior year, the company posted $2.97 EPS. The business’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio is 195.48%.

AbbVie News Roundup Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy? Analyst Ratings Changes Several analysts recently weighed in on the company. Canaccord Genuity Group increased their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Cantor Fitzgerald lifted their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Evercore set a $235.00 price target on AbbVie in a report on Friday, May 15th. Wells Fargo & Company increased their price objective on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.

View Our Latest Stock Report on AbbVie

AbbVie Company Profile (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

See Also Five stocks we like better than AbbVie From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 93,612 shares of the company’s stock, valued at approximately $23,557,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp increased its position in shares of AbbVie by 1.4% during the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after purchasing an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC boosted its position in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after buying an additional 4,190,487 shares in the last quarter. Bank of America Corp DE boosted its position in AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after buying an additional 356,394 shares in the last quarter. Norges Bank bought a new stake in AbbVie during the fourth quarter worth about $5,865,055,000. Finally, Capital Research Global Investors grew its stake in AbbVie by 0.7% during the fourth quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after buying an additional 177,370 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes A number of research firms have recently issued reports on ABBV. Royal Bank Of Canada lifted their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. BNP Paribas Exane increased their price target on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Wells Fargo & Company raised their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. BMO Capital Markets lifted their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Piper Sandler boosted their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.

Check Out Our Latest Analysis on ABBV Insider Buying and Selling at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

AbbVie Trading Down 0.8% Shares of ABBV stock opened at $256.08 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The firm’s 50 day moving average is $252.66 and its 200-day moving average is $228.87. The firm has a market capitalization of $452.44 billion, a price-to-earnings ratio of 72.34, a PEG ratio of 0.85 and a beta of 0.30.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy? About AbbVie (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Featured Articles Five stocks we like better than AbbVie From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

- Strengthens Global Platform, Deepens Vertical Integration and Expands Component Engineering Expertise 

- Reduces Net Leverage to Approximately 2.8 Times Adjusted EBITDA at Close

- Upsizes Annual Run-Rate Synergy Target to $75 Million, Up from Initial $50 Million Estimate

- Hosting Business Update Call on September 2, 2026

, /PRNewswire/ -- Somnigroup International Inc. (NYSE: SGI, "Company" or "Somnigroup") today announced that it has completed its previously announced combination with Leggett & Platt, Incorporated ("Leggett & Platt"), a diversified manufacturer of engineered components and products.

The combined company today operates over 170 manufacturing facilities across 37 countries worldwide and is supported by a global workforce of more than 36,000 colleagues. 

Chairman and CEO Scott Thompson said, "Today marks an exciting milestone for Somnigroup as we complete the combination with Leggett & Platt. Building on nearly 50 years of collaboration, we are bringing together complementary businesses with shared values and a commitment to customer service and product innovation. By combining Leggett & Platt's engineering expertise and manufacturing capabilities with Somnigroup's global scale and industry-leading brands, we are fortifying our foundation for future growth and long-term value creation. The addition of Leggett & Platt deepens our vertical integration, secures a critical part of our supply chain, and adds a highly cash-generative business to our portfolio. We thank the employees of both organizations for their dedication and support throughout this process, as well as our suppliers, advisors, and shareholders for their continued partnership and confidence in our team."

Leggett & Platt Chairman and CEO Karl Glassman said, "For more than 140 years, Leggett & Platt has earned its reputation through engineering excellence, operational discipline, and an unwavering commitment to our customers, and I am incredibly proud of our teams for building that legacy. Joining Somnigroup gives our business the scale and resources to reach new markets and new opportunities, and I am confident this combination creates a stronger future for our employees, our customers, and the industry we have served for generations."

Financial Terms of the Acquisition

The combination was an all-stock transaction valued at approximately $2.3 billion based on Somnigroup's closing share price on August 25, 2026 and inclusive of Leggett & Platt's existing indebtedness. Leggett & Platt shareholders received 0.1455 shares of Somnigroup common stock in exchange for each share of Leggett & Platt common stock they owned. Upon completion of the transaction, former Leggett & Platt shareholders own approximately 9% of the combined company on a fully diluted basis.

Financial Impact

The transaction has reduced Somnigroup's net financial leverage by approximately 0.2 times, and Somnigroup expects to further reduce its leverage towards the midpoint of its target leverage range of 2.0 to 3.0 times adjusted EBITDA by year-end. The Company has identified $75 million in annual run-rate synergies, up from its initial estimate of $50 million, and expects to provide further detail on synergy realization on its business update call.

Leggett & Platt's financial results will be presented as a new reporting segment within the Somnigroup business. Leggett & Platt's sales to Somnigroup's other reporting segments will be eliminated, with no impact to reported Leggett & Platt segment profits. Additionally, consistent with prior expectations and in accordance with GAAP, Somnigroup expects to incur approximately $50 million of annualized non-cash expense from the adjustment to fair value of the acquired Leggett & Platt business, which will primarily impact cost of goods sold, and Somnigroup expects to incur approximately $10 million of annualized non-cash expense from the adjustment to fair value of the acquired Leggett & Platt bonds, which will impact interest expense. The Company anticipates these non-cash items will be financial adjustments in accordance with the terms of its credit facility.

Goldman Sachs & Co. LLC is serving as exclusive financial advisor and Cleary Gottlieb Steen & Hamilton LLP is serving as legal counsel to Somnigroup. J.P. Morgan Securities LLC is serving as exclusive financial advisor and Latham & Watkins LLP is serving as legal counsel to Leggett & Platt.

Business Update Call

The Company will hold a conference call on Wednesday, September 2, 2026 at 8:00 a.m. Eastern Time to discuss the information in this release and provide a preliminary update on its future plans.

The call will be webcast and can be accessed on the Company's investor relations website at investor.somnigroup.com. After the conference call, webcast replays will remain available on the investor relations section of the Company's website for 30 days.

Forward-Looking Statements

This communication contains statements that may be characterized as "forward-looking," within the meaning of the federal securities laws. Such statements might include information concerning one or more of Somnigroup's plans, guidance, objectives, goals, strategies and other information that is not historical information. When used in this release, the words "assumes," "estimates," "expects," "guidance," "anticipates," "might," "projects," "plans," "proposed," "targets," "intends," "believes," "will," "contemplates," "outlook" and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding Somnigroup's expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, run-rate synergies, and plans and objectives of management. Any forward-looking statements contained herein are based upon current expectations and beliefs and various assumptions. There can be no assurance that Somnigroup will realize these expectations, meet its guidance or that these beliefs will prove correct.

Numerous factors, many of which are beyond the Company's control, could cause actual results to differ materially from any that may be expressed herein as forward-looking statements. These potential risks include risks associated with Leggett & Platt's ongoing operations; the ability to successfully integrate Leggett & Platt into Somnigroup's operations and realize synergies from the transaction; the possibility that the expected benefits of the acquisition are not realized when expected or at all; general economic, financial and industry conditions, particularly conditions relating to the financial performance and related credit issues present in the retail sector, as well as consumer confidence and the availability of consumer financing; the impact of the macroeconomic environment in both the U.S. and internationally on Leggett & Platt and the Company; uncertainties arising from national and global events; industry competition; the effects of consolidation of retailers on revenues and costs; and consumer acceptance and changes in demand for Leggett & Platt's and the Company's products and the factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. There may be other factors that may cause the Company's actual results to differ materially from the forward-looking statements. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

About Somnigroup

Somnigroup (NYSE: SGI) is the world's leading bedding company, dedicated to transforming how the world sleeps. With superior capabilities in design, component and finished goods manufacturing, distribution and retail, we deliver breakthrough solutions and serve the evolving needs of consumers in more than 100 countries worldwide through our fully-owned businesses, Tempur Sealy, Mattress Firm, Leggett & Platt, and Dreams.

Our portfolio includes the most highly recognized brands in the industry, including Tempur-Pedic®, Sealy®, Stearns & Foster®, and Sleepy's®, enhanced by Leggett & Platt's diversified component engineering expertise. Our global omni-channel platform and extensive consumer touchpoints enable us to meet consumers wherever they shop, offering a personal connection and innovation to provide a unique retail experience and tailored solutions.

Somnigroup Investor Relations Contact

Lauren Avritt
Investor Relations
Somnigroup International Inc.
[email protected]

SOURCE Somnigroup International

For the quarter ended July 2026, Dollar General (DG - Free Report) reported revenue of $11.29 billion, up 5.2% over the same period last year. EPS came in at $2.23, compared to $1.86 in the year-ago quarter.

The reported revenue represents a surprise of +1% over the Zacks Consensus Estimate of $11.18 billion. With the consensus EPS estimate being $2.00, the EPS surprise was +11.5%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Dollar General performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Ending store count: 21,148 compared to the 21,152 average estimate based on 22 analysts.Total selling square footage: 161.52 Msq ft versus the 22-analyst average estimate of 161.41 Msq ft.Same-Store Sales growth: 3.5% compared to the 2.6% average estimate based on 22 analysts.Store closings: 33 versus 24 estimated by 19 analysts on average.New store openings: 126 versus 132 estimated by 19 analysts on average.Net Sales per square foot: $69.90 versus the 17-analyst average estimate of $69.13.Net Sales Per Store: $0.53 million compared to the $0.53 million average estimate based on 15 analysts.Net Sales by Category- Consumables: $9.26 billion versus $9.21 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +5% change.Net Sales by Category- Seasonal: $1.19 billion compared to the $1.15 billion average estimate based on seven analysts. The reported number represents a change of +7.4% year over year.Net Sales by Category- Home products: $536.57 million versus the seven-analyst average estimate of $532.85 million. The reported number represents a year-over-year change of +4.8%.Net Sales by Category- Apparel: $303.09 million versus the seven-analyst average estimate of $300.55 million. The reported number represents a year-over-year change of +4.5%.View all Key Company Metrics for Dollar General here>>>

Shares of Dollar General have returned -4.6% over the past month versus the Zacks S&P 500 composite's +3.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Dollar General plans to increase its selection of $1 items by the end of the year. Jakub Porzycki/NurPhoto via Getty Images Dollar General is doubling down on the $1 price point.

A selection of 600 items priced at $1 each, which the chain calls "Value Valley," had comparable sales growth of 16% during the company's second quarter — a much faster clip than broader same-store sales growth of 3.5%, it said on Thursday.

In total, Dollar General stocks about 2,000 items that cost $1 each. It expects to grow that number by 40% in the second half of 2026 in time for the holiday shopping season, COO Emily Taylor said on the retailer's earnings call.

Expect that selection to grow "even more so into 2027," CEO Todd Vasos said. "We have got real plans to expand that $1 price point to offer even more value for the consumer," he added.

Dollar stores used to be true to their name, with everything on their shelves priced at $1. Inflation has changed that, though: In 2021, Dollar Tree raised prices on most items to $1.25 and has since experimented with items priced at several dollars each.

That's a different direction than Dollar General appears to be taking, said Arielle Feger, a senior analyst at EMARKETER, Business Insider's sister company.

While Dollar General has long sold items that cost well over $1 each, many of those items are food and other consumables that draw people into the store, Feger said. The chain began adding freezers stocked with food items priced at $1 each to its stores earlier this year, Vasos said on the company's last earnings call in June.

Dollar Tree's $1 item selection, by contrast, skews more toward discretionary items, such as home decor and toys.

Dollar General's strategy is similar to the classic grocery store strategy of selling eggs and milk as cheaply as possible — even at a loss, potentially — to boost overall sales, Feger said.

"It gets people in the door, and it gets them to continue to come back," she said.

That strategy is particularly meaningful to customers who are trying to save money, Vasos said on Thursday's earnings call.

Dollar General's average customer is "still gainfully employed" and "is seeing some gains in her income levels," the CEO said. But inflation and rising gas prices this year have offset that income gain, Vasos said, leading many customers to visit its stores more often and buy less each trip.

By expanding its selection of $1 items, Dollar General will likely continue to attract customers, Feger said.

"Consumers are habitual," she said. "We go to the same places, we expect the same things."

Do you have a story idea about Dollar General or Dollar Tree? Contact this reporter at [email protected] or via encrypted messaging app Signal at 808-854-4501. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.

Read next

Alex Bitter You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Alex Bitter is a senior retail reporter covering the gig economy, food, and retail. His work focuses major gig delivery and ride-hailing apps, including Uber, Lyft, DoorDash, Instacart, and Walmart's Spark. He is interested in everything from what it's like to work on the apps to the companies' business strategies.Some of his recent stories feature gig workers who have been deactivated on the apps, DoorDash hiring traditional employees to make deliveries, gig workers' use of bots, and gig work expanding into new professions, such as nursing.Alex has also written about Aldi's US expansion, Starbucks' turnaround efforts, and the fallout from Kraft-Heinz's budget cutting. Convenience store chain Sheetz ended its "smile policy" after his reporting.Before joining Insider in September 2020, he wrote about consumer and retail companies for S&P Global Market Intelligence. He's a graduate of the University of Hawai'i at Mānoa and grew up on the Big Island.Alex lives in the Washington, DC, area, where you can find him studying ancient coins or searching for Civil War artifacts with his metal detector in his free time.Got a tip? Reach out at [email protected] or via encrypted messaging app Signal at +1 (808) 854-4501.

Shopping Retail Grocery More

Key Takeaways Simon Property Group launched a commerce media platform spanning more than 200 destinations.The network combines first-party data, digital displays and other channels with flexible campaign targeting.Simon Property Group will offer verified insights and closed-loop attribution to measure ad returns. Simon Property Group (SPG - Free Report) has launched Simon Media Network, a new commerce media platform designed to help brands reach high-intent consumers across its portfolio of more than 200 shopping, dining, entertainment and mixed-use destinations. The platform combines Simon’s physical properties, first-party consumer intelligence and marketing capabilities to connect advertisers with consumers where they already shop and spend time.

The initiative gives Simon a differentiated position in the fast-growing retail media market. Unlike traditional retail media networks that are largely based on transactions from a single retailer, Simon can draw insights from consumer activity across a broader ecosystem of stores, restaurants, entertainment venues and lifestyle experiences. Its properties generate billions of visits globally and more than $100 billion in commerce, giving the company a sizable pool of real-world behavioral data.

Advertisers will be able to run campaigns across Simon’s digital displays, experiential activations, ShopSimon.com, the Simon+ loyalty program, social and digital channels, as well as off-platform media. Campaigns can also be targeted nationally, regionally, by market or at individual properties, giving brands flexibility in how they deploy advertising budgets.

A key selling point is measurement. Simon says the network will use its first-party consumer intelligence to provide verified insights on visitation, transactions and engagement, while offering closed-loop attribution to help advertisers measure incremental return on advertising spend. This could make Simon’s physical traffic and consumer data more valuable by converting them into a measurable advertising product rather than relying solely on traditional mall-based revenues.

OutlookFor SPG, the launch is strategically positive. Simon Media Network creates an additional monetization opportunity from an asset base it already owns. If advertiser adoption scales, it could add a higher-margin, less capital-intensive revenue stream, deepen relationships with retailers and brands, and improve the economics of Simon’s properties beyond rent and occupancy-related income.

Over the past three months, shares of this Zacks Rank #3 (Hold) company have gained 3.9% compared with the industry’s growth of 0.5%.

Image Source: Zacks Investment Research

Stocks to ConsiderSome better-ranked stocks from the broader REIT sector are American Tower (AMT - Free Report) and Lamar Advertising (LAMR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for AMT’s 2026 FFO per share has been revised upward marginally to $11.07 over the past week.

The consensus estimate for LAMR’s 2026 FFO per share has been revised up 1.4% over the past month to $8.93.

Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.

The Kraft Heinz Company (Nasdaq: KHC) (“Kraft Heinz” or the “Company”) today announced that it will transfer the listing of its common stock to the New York Stock Exchange (NYSE). Kraft Heinz expects its common stock to begin trading on the NYSE on September 14, 2026, under its existing ticker symbol, KHC.

“Our move to the New York Stock Exchange marks an exciting milestone in Kraft Heinz's transformation. We believe the NYSE is a natural home for Kraft Heinz as we enter our next chapter, reflecting the strength of our iconic portfolio, our global scale, and our focus on creating long-term shareholder value,” said Steve Cahillane, CEO of Kraft Heinz.

“We are proud to welcome Kraft Heinz to the NYSE, where it joins our community of iconic American brands and industry leaders,” said Lynn Martin, President, NYSE Group. “Kraft Heinz shares our commitment to innovation with its own unique mission to deliver high-quality, delicious and affordable foods to people around the world. We look forward to supporting the company as it continues to grow its global investor base and fulfill its promise to consumers everywhere.”

ABOUT THE KRAFT HEINZ COMPANY

Kraft Heinz (Nasdaq: KHC) is one of the world’s largest food and beverage companies, with approximately $25 billion in net sales in 2025 and a portfolio of iconic brands enjoyed by consumers in more than 40 countries. By investing in our capabilities and brands, including Heinz, Kraft, Philadelphia, Primal Kitchen, and Lunchables, we are unlocking the full power of our portfolio. We deliver high-quality, great-tasting, and affordable food for the consumers of today, while shaping the future of food. Learn more at www.kraftheinzcompany.com.

Category: Financial

View source version on businesswire.com: https://www.businesswire.com/news/home/20260826560484/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Sunshine State drivers now have access to tech-powered coverage built for how people actually drive

, /PRNewswire/ -- Lemonade (NYSE: LMND), the tech-first insurance company, today announced the launch of Lemonade Car in Florida, one of the largest car insurance markets in the country. Florida drivers can now access Lemonade Car which is built for today's modern lifestyle to help consumers save.

"Florida is one of the largest and fastest-growing personal auto markets in the country, including millions of working-age, digital-native drivers concentrated in fast-growing metros like Miami, Tampa, Orlando, and Jacksonville. These drivers are the type of digital-first consumers who want insurance that's fast, mobile, and fair, based on how they drive, that gives discounts for cars like EVs, and more," said Shai Wininger, President and Co-Founder of Lemonade.

With this expansion, Lemonade Car is now available in states representing nearly 50% of the U.S. car insurance market, marking a particularly significant step in the company's accelerating national rollout.

Bundling is also available for Floridians who already use Lemonade for renters, homeowners, and pet insurance.

Drivers can explore coverage options or get a quote in minutes at lemonade.com/car.

About Lemonade

Lemonade's mission is to become the most loved insurance company in the world. As a customer-centric tech company, we created an insurance experience across Renters, Home, Pet, Car, and Life that is smart, instant, and delightful. Our team of 1,200+ Lemonade Makers makes it possible for over 3M customers throughout the US, UK and Europe to get coverage instantly, with nearly half of claims paid in a matter of seconds. Powered by AI and social impact, Lemonade is a purpose-built, technology-first insurance carrier. A Certified B-Corp, our commitment to social impact is embedded in every aspect of the company, and our Giveback program, which donates a percentage of leftover premiums to nonprofits selected by our community, has donated over $10M to organizations in need.

SOURCE Lemonade, Inc.

A value investor ran Palantir through the same stress test he uses on every high-growth stock, and the result left him with a very specific price and a frank admission about what he still cannot explain.

On the latest We Study Billionaires episode, Preston Pysh admitted something value-leaning investors have quietly been thinking about Palantir (NASDAQ:PLTR | PLTR Price Prediction). The headline P/E overstates how expensive the company really is because the underlying growth is genuinely rare. Pysh still would not buy the stock here. His line, delivered with Daniel Mahncke and Shawn O’Malley on episode TIP841, was simple: “If you see the stock below $100 and nothing changes, count me in.”

Palantir closed Thursday at $185.93, well above that level, after gaining 50.51% in the past month alone on a blowout Q2 report. The $100 print is the easy takeaway. The more useful takeaway is the framework Pysh used to arrive at it, because that framework applies to every other AI-adjacent story in the market right now.

Halved-Growth Stress Test Pysh’s tool for fast-growing companies is a thought experiment: imagine the next earnings report comes in with growth cut in half, and ask whether you can explain why. If you can, you understand the business. If you cannot, you are along for the ride.

He compared two cases. Slower growth at Lululemon (NASDAQ:LULU) is easy to diagnose: customers either switched to a competitor or stopped spending. Slower growth at The Trade Desk (NASDAQ:TTD) is much harder to parse, and Pysh admitted, “I have absolutely no clue why the top line growth is declining, and I also have no clue where the bottom would be.”

Palantir sits in the harder bucket. Q2 U.S. commercial revenue grew 149% year-over-year, and total revenue grew 92.83%. If those numbers halved next quarter, would a retail shareholder be able to name the reason? Was it AIP land-and-expand hitting a natural ceiling, government procurement timing, or competition from hyperscalers offering their own operational AI layers?

Pysh’s answer is no: “I’m just not sure how many would still claim to understand the business that well.” That is the correct thing for a disciplined investor to say when the machinery under a stock is opaque.

Owner Versus Speculator Stig Brodersen framed the same idea from the other side. “To be an investor, that really means you have to think like an owner and feel like you understand all of the variables affecting the business. And so if you’re just buying a stock and you don’t have that owner mindset… well then you’re just speculating.”

The line between investing and speculating has little to do with the asset or the holding period. It has to do with whether you can articulate the variables driving the outcome. Much of Palantir ownership today sits on the speculative side of that line, which is acceptable if the position is sized accordingly. It becomes dangerous when someone has talked themselves into believing the position is conservative because the company is profitable and the CEO is confident. Brodersen noted that a real selloff could make Palantir “a really interesting entry point for folks who are willing to speculate more.” That is the useful framing.

Fair Reading of the Bull Case Pysh left the door open wider than a passing listener might notice. His colleague Daniel Mahncke ran a two-scenario DCF and concluded that on Karp’s own guidance, “the price-to-sales ratio would decline from about 60 today to about 20. And if you trust Karp’s estimates, the fair value is at about $240.”

The Q2 report supports that scenario in the short term. GAAP operating income reached $912 million, free cash flow hit $1.220 billion, and management raised FY2026 revenue guidance to $8.150 to $8.158 billion per the Q2 8-K.

If the Ontology platform is a real switching-cost moat inside government and enterprise workflows, forward multiples compress quickly. Pysh himself said that a better understanding of Ontology could change his view, and that the concession matters.

Cost of Drawing a Price Line Setting a level and waiting is a real strategy with a real cost. Palantir is up 623.18% over five years and roughly 2,809% from its January 2023 low. A business compounding this fast may simply never revisit $100.

Waiting for a level that never arrives is how disciplined investors miss decade-long winners. It is also how disciplined investors avoid ruinous drawdowns, because a forward P/E of 108x leaves no room for a stumble (we wrote a free handbook on riding a mania without giving back the gains, here). Both statements are true at once.

Pysh’s position reflects intellectual discipline. He is refusing to underwrite something he cannot fully explain, which is more useful for a retail investor to hear than another price target. The reader’s job is to decide which side of Brodersen’s line they are on, and then size accordingly.

Contact [email protected] for any questions or corrections.

A federal court just ruled the Pentagon's retaliation against an AI supplier illegal, and the fallout lands squarely on one of Palantir's most critical defense programs before a make-or-break September deadline.

A federal judge permanently blocked the Pentagon’s designation of Anthropic as a supply-chain risk, calling the action illegal and baseless. Judge Rita Lin concluded the government retaliated after Anthropic resisted unrestricted use of Claude for mass surveillance and autonomous weapons.

Palantir (NASDAQ:PLTR | PLTR Price Prediction) was not a party to the case, but the ruling touches the company’s most important defense AI program because Palantir’s Maven Smart System runs Anthropic’s Claude inside it, and the Pentagon plans to designate Maven as an official program of record by the end of September. Palantir closed at $186.29 Friday, up 51.46% over the past month. The question is whether removing the Anthropic overhang lowers Palantir’s execution risk enough to justify current valuations.

What the Court Ruling Changes Palantir gets no direct legal benefit as a non-plaintiff.

The practical effect: Palantir likely avoids rewriting orchestration inside classified environments on a compressed timeline, which is expensive and slow. The ruling does not require the Pentagon to retain Anthropic as a supplier, guarantee incremental Palantir revenue, or prevent a government appeal.

It shrinks tail risk that Maven’s model layer gets forcibly reshuffled before the program graduates to permanent funding status. Timing matters more than total addressable market for program-of-record designations.

Maven, Money, and Program of Record Maven’s existing contract ceiling was raised to $1.3 billion in 2025, and Palantir separately holds an Army agreement worth up to $10 billion. A ceiling is the maximum the government may spend, not revenue Palantir has earned.

The FY 2027 President’s Budget requests $2.3 billion for the Maven Smart System and Joint Fires Network to deliver joint command and control, part of a $58.5 billion AI investment line item. On the Q2 call, Shyam Sankar said “Maven continues to deliver for the joint force, from the factory floor to the foxhole” and that Maven now has over 25,000 builders using it. Management also said the Department of War trailing twelve-month revenue is “less than 25 basis points of the Pentagon’s budget”.

Palantir’s U.S. government revenue grew 90% year-over-year to $809 million in Q2, a level that a program-of-record catalyst would compound.

Why Integration Beats Any Single Model Palantir’s value sits in the integration layer above whichever frontier model the Pentagon picks. Sankar told analysts “We have a product that allows you to switch out models”, and Alex Karp added “It’s not about being beholden to one model. It’s about bringing the right models to bear for the right purposes.”

Sankar also described bringing in NVIDIA (NASDAQ:NVDA)’s Nemotron Ultra and finding five production tasks where a standard Nemotron Ultra model without post-training beat frontier models within 24 hours. If AIP is the orchestration and evaluation surface, model swaps become a platform feature rather than a contract threat. That is the real version of the sovereignty pitch.

The ruling reduces execution risk for Maven, and the broader thesis is that Maven deepens the question of whether Claude stays or goes.

Valuation Remains the Core Question Palantir trades at a forward P/E near 110x against a price-to-sales ratio of about 73x. Any bullish case must survive those numbers.

The offset is growth quality. Q2 revenue rose 93% year-over-year with a Rule of Forty score of 155 and adjusted free cash flow of $1.22 billion. The market is not fully convinced this holds. Polymarket assigns its highest probabilities to $180 at 0.315 and $192 at 0.305, and the August 31 directional market leans Down at 0.53. The $191.68 average analyst target is barely above spot, so the sell side is not underwriting a fresh leg higher on this news alone.

The ruling lowers execution risk on Maven’s path to program-of-record status without changing the valuation math. Watch the September designation closely, but do not expect overnight repricing.

Contact [email protected] for any questions or corrections.

Bristol Myers Squibb (BMY.N) has ended its partnership with cell therapy startup Cellares that aimed to expand ​the manufacturing of its personalized blood cancer therapy, a company spokesperson ‌told Reuters on Tuesday.

Bristol Myers determined that Cellares' cell therapy manufacturing platform, Cell Shuttle, could not meet the requirements to make its CAR-T therapy, Breyanzi, at commercial scale, the ​spokesperson said.

Cellares strongly disagrees with this characterization, the company told Reuters. The ​Cell Shuttle platform has already manufactured a Good Manufacturing Practice-compliant ⁠cell therapy product in an FDA-regulated clinical program, it said.

Personalized CAR-T therapies ​have transformed care for some blood cancer patients, but remain difficult and expensive ​to produce.

Breyanzi, first approved by the U.S. FDA in 2021, is used to treat lymphoma and other blood cancers. It generated $1.36 billion in sales in 2025.

Endpoints News first reported the development ​on Tuesday.

CELLARES TO CUT 100 JOBS
Cellares CEO Fabian Gerlinghaus had disclosed the ​loss of a "large pharmaceutical customer" in a LinkedIn post over the weekend, adding that this would ‌force the ⁠company to "resize" its workforce.

The startup will lay off about 100 employees at its South San Francisco facility on October 20, according to a notice filed with the California Employment Development Department on August 21. It will give affected workers ​at least 60 ​days' notice and ⁠full salary and benefits until October 20.

The notice did not mention severance packages.

Cellares did not respond to a Reuters ​request for comment on the layoffs.

The companies signed a deal ​in 2024 ⁠worth up to $380 million under which Bristol Myers reserved manufacturing capacity across the U.S., the European Union and Japan for CAR-T therapies.

Bristol Myers' decision only applies ⁠to Breyanzi ​and its approved manufacturing process.

CAR-T therapies work by ​removing a patient's immune cells, reprogramming them in a lab to fight cancer and infusing them ​back into the body.

Ancora Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,068 shares of the biopharmaceutical company’s stock, valued at approximately $1,387,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the 2nd quarter valued at $1,436,115,000. Canada Pension Plan Investment Board purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $241,223,000. Legal & General Group Plc bought a new position in shares of Bristol Myers Squibb during the second quarter valued at about $980,862,000. The Manufacturers Life Insurance Company purchased a new position in Bristol Myers Squibb during the second quarter worth about $125,419,000. Finally, Van Hulzen Asset Management LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter worth about $975,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures? Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action? Wall Street Analysts Forecast Growth Several research firms have commented on BMY. Jefferies Financial Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Bank of America reduced their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Finally, TD Cowen started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average target price of $66.06. View Our Latest Research Report on BMY

Insider Activity In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Trading Down 0.9% Shares of BMY opened at $66.93 on Friday. The business’s 50-day moving average price is $61.51 and its 200-day moving average price is $59.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The stock has a market cap of $136.73 billion, a PE ratio of 14.74, a P/E/G ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Recommended Stories Five stocks we like better than Bristol Myers Squibb Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Albemarle Corp. (NYSE:ALB) stock traded lower Tuesday as JPMorgan reduced its earnings estimates and price forecast for the lithium producer.

Analyst Jeffrey Zekauskas maintained a Neutral rating and lowered the December 2027 price forecast to $140 from a previous December 2026 forecast of $160.

Lower Lithium Prices Pressure Albemarle OutlookJPMorgan cut its 2026 adjusted EBITDA estimate by 14.4% to $2.88 billion from $3.37 billion. It also reduced its 2027 estimate by 18.4% to $2.93 billion from $3.59 billion.

The firm lowered its 2026 adjusted earnings estimate to $12.05 per share from $14.20. Its 2027 estimate fell to $11.65 from $15.35.

The revisions reflect weaker lithium prices. China lithium carbonate prices averaged $24,810 per metric ton in the second quarter. However, they have averaged about $21,625 so far in the third quarter.

JPMorgan now expects lithium prices to remain in the low-$20-per-kilogram range. The firm previously modeled prices in the mid-$20 range. Each $1-per-kilogram change could affect Albemarle’s annual EBITDA by about $250 million.

Third-Quarter Profit Expected to FallJPMorgan expects third-quarter adjusted EBITDA of $668 million. That would fall from $858 million in the second quarter but rise from $226 million a year earlier.

The firm also expects lower quarterly lithium sales volume and a weaker product mix.

Meanwhile, Albemarle faces delays at the Greenbushes CGP3 plant following a June fire. The plant restarted Aug. 1, but JPMorgan now expects full production rates by the end of the first quarter of 2027.

The bank said Albemarle trades near its price forecast and carries a fair valuation for a high-quality but volatile lithium producer.

Albemarle Price ActionALB Price Action: Albemarle shares were down 5.16% at $134.21 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo via Shutterstock 

Read Next

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

PDD Today

$85.69 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

$71.94▼

$139.419.44

$117.17

On paper, PDD Holdings Inc. NASDAQ: PDD gave investors plenty to cheer in its Aug. 24 earnings report, comfortably beating expectations on earnings. Shares of the Chinese e-commerce giant duly popped at the open, yet by the closing bell, that early enthusiasm had evaporated and the stock slipped into the red, a telling sign that all isn't quite as rosy as the headline beat suggested. A modest rebound in Aug. 25 trading did little to dispel the doubts.

That muted response speaks volumes about the questions still hanging over the owner of budget shopping apps Pinduoduo and Temu. The shares remain down almost 25% for the year, and the failure to hold on to that post-earnings pop puts a nascent recovery, one that has seen the stock climb around 20% since late June, at risk of stalling.

Get PDD alerts:

So why did a profit beat fail to win investors over? The answer lies not in the numbers the company beat, but in the ones it missed, and in the risks that refuse to go away.

A Mixed Report Beneath the SurfaceFor starters, the results were far more mixed than the headline profit beat implies. While earnings came in ahead of forecasts, revenue fell short of expectations, growing a respectable but underwhelming 8% year on year. For a company long prized as a growth machine, a top-line miss is exactly the kind of thing to give investors pause.

More troubling was the direction of net income. Despite the beat, the company's bottom line declined markedly from a year earlier, with net income falling by double digits. In other words, PDD is making less money than it was 12 months ago, even as its sales grow, a classic warning sign of a business under mounting cost pressure.

That combination, slowing revenue growth paired with shrinking profits, gets to the heart of why the market hesitated: the company is continuing to spend heavily in pursuit of longer-term growth.

The Squeeze on ProfitabilityAt the core of the bear case is exactly this erosion of profitability, as PDD plows money back into its platforms. The company is investing heavily in merchant subsidies and AI-powered shopping tools, and while that spending may support growth in the long run, it's clearly weighing on margins now.

The worry is that the pressure only intensifies from here: should competition force PDD to keep spending to defend its position, profits could stay under strain for some time. For a stock whose appeal has long rested on turning growth into hefty profits, any sign that the formula is breaking down is bound to unsettle the market.

Temu's Regulatory CloudBeyond the margin worries lies a thornier challenge: mounting regulatory scrutiny facing Temu, the group's fast-growing international arm. Management acknowledged the difficulty head-on, noting that the global trade and regulatory landscape has continued to shift, creating significant challenges even as it opens fresh opportunities.

That careful language reflects a real overhang. Temu's meteoric rise was built in part on shipping ultra-cheap goods across borders, a model now squarely in regulators' sights. Changes to the rules on low-value imports, along with tighter customs enforcement and new tariffs, threaten to raise costs and complicate the very growth story that made Temu so compelling.

The Battle on Home TurfIf the international picture is clouded, the domestic one is no less fierce. Back in China, competition among the big e-commerce players has rarely been more intense, and the result has been a costly spending war that has squeezed margins across the sector.

There is some comfort for PDD here, since compared with certain rivals, many of whose profits have taken an even heavier battering, the company has proven relatively resilient so far. But resilience is not immunity. As long as the price war rages, PDD may have to keep spending heavily to hold its ground, adding more pressure to the margins that investors are already fretting about.

Cheap, But Not Yet ConvincingPDD Stock Forecast Today12-Month Stock Price Forecast:
$117.17
36.73% Upside

Hold
Based on 15 Analyst Ratings

Current Price$85.69High Forecast$170.00Average Forecast$117.17Low Forecast$80.00PDD Stock Forecast Details

Weighing it all up, the market's tepid reaction makes sense. A profit beat is all well and good, but set against a revenue miss, falling profits, and a thicket of regulatory and competitive risks, it was never likely to spark a lasting rally on its own. The muted response looks less like an overreaction than a sober assessment of a decidedly mixed picture.

That caution is shared more widely. Following the results, Deutsche Bank reiterated its Hold rating, a stance that chimes with the broader MarketBeat consensus rating of Hold. The message from both is one of watchful patience rather than conviction in either direction.

For now, PDD finds itself in a familiar bind—cheap enough to tempt bargain hunters, yet saddled with enough uncertainty to keep the doubters at bay. Whether the recovery regains its footing will depend less on any single earnings beat than on whether the company can prove its profits, and not just its sales, are built to last.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in PDD Right Now?Before you consider PDD, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDD wasn't on the list.

While PDD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report